24 February 2025 in International Journal of Infectious Diseases
We report the first confirmed cases of Zika virus (ZIKV) disease (ZVD) in Kenya and provide the associated genomic sequences. The study is part of a prospective febrile illness surveillance study in Kenya. A cluster of ZVD cases was identified in patients with fever presenting at King Fahd Referral Hospital, Lamu Island. Clinical signs resembled those caused by dengue or malaria and included fever, chills, muscle and joint pains, and headache. The Biofire Film Array Global fever panel (BioFire Diagnostics, UT, USA) identified ZIKV in three of five blood samples. RNA extracted from plasma was used for sequence library preparation and subsequent viral enrichment using the VirCapSeq-VERT probe set designed at the Center for Infection and Immunity, Columbia University. Enriched libraries were sequenced on the NextSeq 2000 (Illumina, San Diego, CA, USA). Assembled genomes were classified into lineages and a spatio-temporal phylogeny inferred with Nextstrain v8.5.3. Assembled genomes produced contigs covering between 3363 and 10,950 nt that mapped to the Asian lineage of ZIKV and branched with genomes from India. Mutation profiling revealed viral strains with potentially enhanced transmission and immune evasion capabilities. The presence of the more transmissible Asian lineage ZIKV that has previously caused large outbreaks of ZVD in the Americas raises significant public health concern.
21 July 2022 in African Journal of Laboratory Medicine
Background: The Basic Science Laboratory (BSL) of the Kenya Medical Research Institute/Walter Reed Project in Kisumu, Kenya addressed mass testing challenges posed by the emergent coronavirus disease 2019 (COVID-19) in an environment of global supply shortages. Before COVID-19, the BSL had adequate resources for disease surveillance and was therefore designated as one of the testing centres for COVID-19. Intervention: By April 2020, the BSL had developed stringent safety procedures for receiving and mass testing potentially infectious nasal specimens. To accommodate increased demand, BSL personnel worked in units: nucleic acid extraction, polymerase chain reaction, and data and quality assurance checks. The BSL adopted procedures for tracking sample integrity and minimising cross-contamination. Lessons learnt: Between May 2020 and January 2022, the BSL tested 63 542 samples, of which 5375 (8.59%) were positive for COVID-19; 1034 genomes were generated by whole genome sequencing and deposited in the Global Initiative on Sharing All Influenza Data database to aid global tracking of viral lineages. At the height of the pandemic (August and November 2020, April and August 2021 and January 2022), the BSL was testing more than 500 samples daily, compared to 150 per month prior to COVID-19. An important lesson from the COVID-19 pandemic was the discovery of untapped resilience within BSL personnel that allowed adaptability when the situation demanded. Strict safety procedures and quality management that are often difficult to maintain became routine. Recommendations: A fundamental lesson to embrace is that there is no ‘one-size-fits-all’ approach and adaptability is the key to success.
24 July 2026 in PLOS Global Public Health
Given limited data on SARS‑CoV‑2 transmission and immunity in rural, low‑vaccine‑coverage settings, we evaluated infection rates and population‑level neutralizing antibody increase in a rural community in western Kenya. The study was conducted at the KEMRI/WRAIR-Africa Health Demographic Surveillance System that has a population of 160,000. Clusters of households that had representative demographics were identified and individuals invited to participate in six cross-sectional surveys that targeted 234 participants at each survey, two months apart, conducted between April 2021 and March 2022, during which time, the Alpha, Delta and Omicron waves dominated. At each survey, participants provided naso-pharyngeal samples for SARS-CoV-2 detection and serum for measuring neutralizing antibodies (NAbs) using surrogate virus neutralizing test which assessed inhibition of RBD–ACE2 binding. 69% (917/1329) of the participants were females. By RT-qPCR, SARS-CoV-2 increased from 3% (7/224) at survey one (April 2021) to 24% (55/229) by survey two (June 2021), and thereafter decreased to zero, only to rise to 10% (23/234) during the January 2022 Omicron wave. NAbs increased from 18% (40/224) at survey one to 86% (202/234) by end of the study. The quantity of NAbs rose from geometric mean of 0.42 U/mL at survey one to 9.4 U/mL by survey six. Females had higher NAbs (3.73U/mL, 95% CI), compared to 1.98 U/mL, 95% CI (p = 0.0146) for males. NAbs quantities increased with age: 2.1 U/mL for 60 years. The increase in population-level NAbs is consistent with widespread exposure to the virus during the study period. As caveat, causality of NAbs for the decline in SARS‑CoV‑2 infections cannot be inferred with confidence, because other factors such as the use of non‑pharmaceutical interventions and other individual-level variables were not measured.